Agatheeswaran and colleagues reported that MEF2C and polypyrimidine tract-binding protein 2 (PTBP2) are direct targets of miR-223, and are upregulated in CML. The gene discussed is PTBP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.